Carbon accounting and sustainability reporting for pharma, biotech, and CDMOs.
Higher Impact helps life sciences companies with complex facilities, suppliers, products, and customer expectations build credible Scope 1-3 inventories and sustainability reporting programs.
Pressure is rising. Ownership is fragmented.
Pharma and life sciences companies are facing growing pressure from customers, investors, regulators, and supply chain partners. But ownership is often fragmented across sustainability, EHS, procurement, facilities, finance, quality, legal, and corporate affairs. Higher Impact helps connect the dots and turn scattered data into a defensible program.
Where pharma and life sciences teams typically engage Higher Impact.
First Scope 1-3 Baseline
For companies building their first credible GHG inventory across facilities, fleets, purchased energy, procurement, logistics, commuting, travel, and waste.
Scope 2 Market-Based Review
For companies using onsite solar, RECs, PPAs, green tariffs, or supplier-specific electricity data that need confidence before reporting or assurance.
Scope 3 Methodology Enhancement
For companies moving from spend-based estimates to activity-based, hybrid, and supplier-informed methods where the data supports it.
Supplier Data Program
For companies that need to engage suppliers, collect emissions data, use EcoVadis outputs, or identify priority suppliers for future improvement.
Investor-Ready Sustainability Program
For PE-backed, pre-IPO, or growth-stage companies that need carbon accounting, CDP, EcoVadis, TCFD, SBTi, net zero, and annual reporting workflows.
Product Footprint Readiness
For companies beginning to face product-level carbon questions from customers, partners, or future regulation.
The frameworks we work in every week.
Anonymized examples of pharma and life sciences work.
Global pharma services / CDMO
Supported a global pharma services organization operating across a complex, multi-site environment through a sustainability maturity journey spanning Scope 1–3 carbon accounting, Scope 3 methodology enhancement, supplier data workflows, automated utility integrations, and assurance-ready reporting.
- Built a first enterprise-wide carbon accounting foundation
- Improved Scope 3 precision through supplier-informed and activity-based methods
- Established repeatable supplier engagement and data quality workflows
- Automated utility data collection across global sites
- Reduced internal burden while improving reporting defensibility
Public life sciences company
Supported Scope 2 market-based validation and Scope 3 methodology enhancement for a life sciences company preparing for assurance and improving the defensibility of its carbon accounting approach.
- Reviewed Scope 2 market-based treatment and REC claimability
- Supported documentation for assurance readiness
- Developed a practical Scope 3 methodology enhancement approach
- Built on existing supplier and activity data rather than starting from scratch
- Created a roadmap for improving precision over time
Selected client work performed directly or delivered through partner ecosystems. Client names are anonymized.
Need help translating pharma sustainability pressure into a practical plan?
Start with a 30-minute intro call. We'll quickly map where you are, what is driving the pressure, and the right next step.